Etiket: MorphoSys
Outlook: MorphoSys presents results for the past quarter
MorphoSys opens the books – what analysts expect. MorphoSys will present the quarterly figures for the most recent quarter of the year – closing date December 31, 2023 – at…
Novartis wants to swallow Morphosys
BASEL (dpa-AFX) – The Swiss pharmaceutical company Novartis wants to take over the biotech company MorphoSys. Morphosys shareholders will be offered 68 euros per share, Novartis and Morphosys announced on…
Insider – Novartis wants to take over biotech company Morphosys
New York (Reuters) – According to insiders, the Swiss pharmaceutical company Novartis is in advanced talks to take over the biotech company Morphosys. Novartis prevailed against the drug manufacturer Incyte,…
SHARE IN FOCUS: Morphosys price slips after Pelabresib data on Tradegate
FRANKFURT (dpa-AFX Broker) – The study data for the cancer drug Pelabresib caused a lot of nervousness in MorphoSys shares on Tuesday morning. Recently the price slipped massively. At their…
The expert opinions on MorphoSys shares in October 2023
This is how experts recently assessed MorphoSys shares. 3 analysts published their analysis of MorphoSys shares last month. 2 experts recommend buying MorphoSys shares, 1 expert recommends holding MorphoSys shares.…
AFTER-HOURS/XDAX -0.1% to 15,708 points – Morphosys
FRANKFURT (Dow Jones)–Reluctance characterized after-hours trading on Tuesday. Among the individual stocks, Morphosys stood out, rising by almost 4 percent in the evening. The US Food and Drug Administration (FDA)…
MorphoSys stock jumps: MorphoSys clearly limits loss in 2022
shares in this article Analysts had expected a significantly worse result. The group, which specializes in new cancer therapies, benefited in 2022 from higher sales of its drug Monjuvi and…
MorphoSys Shares Stronger: License granted for preclinical oncology program
To make it easier for you to keep track of the large number of messages that appear every day for a company, we have divided the news feed into the…
Hot Stocks Today: Strategic Short on Dow Jones and S&P 500 – is MorphoSys cheap now?
Live at 6 p.m.: AMD, Nvidia and Intel – How badly are US techs still suffering from the interest rate turnaround? The high interest rates are particularly hard on the…
Investors in Europe continue to grab – Morphosys crashes
FRANKFURT (Reuters) – The prospect of more cautious rate hikes in the US and an easing of pandemic restrictions in China are attracting more investors to European stock markets. Dax…